Form 4: KORU Medical CFO Adams Reports Equity Transactions

KORU Medical Systems CFO Thomas Edward Adams reported the vesting of restricted stock units, subsequent tax-related share disposals, and new equity awards including RSUs, PSUs, and stock options.

Summary

• Thomas Edward Adams, Chief Financial Officer of KORU Medical Systems, Inc. (KRMD), acquired 5,404 shares of common stock on March 16, 2026, upon the vesting of restricted stock units.
• Concurrently, 2,123 shares of common stock were disposed of at a price of $4.28 per share to satisfy tax obligations related to the RSU vesting.
• Following these transactions, Adams beneficially owns 3,281 shares of common stock directly.
• Adams was granted 38,918 Restricted Stock Units (RSUs) on March 17, 2026, under the Issuer's 2024 Omnibus Equity Incentive Plan. These RSUs will vest in equal increments on March 17, 2027, and each subsequent first, second, and third anniversary.
• Additionally, 38,918 Performance Stock Units (PSUs) were granted on March 17, 2026. These PSUs will vest based on the achievement of certain performance conditions as of December 31, 2028, with potential payout ranging from 0% to 150% of the reported amount. Full vesting at 100% occurs upon a change in control prior to December 31, 2028.
• Adams also received an option to buy 58,490 shares of common stock at an exercise price of $4.35 per share, granted on March 17, 2026, with an expiration date of March 17, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting routine executive compensation that aligns management incentives with long-term shareholder value through new equity awards, despite a minor share disposal for tax purposes.

Positives

• The grant of new Restricted Stock Units (RSUs), Performance Stock Units (PSUs), and stock options to the Chief Financial Officer aligns management's interests with long-term shareholder value creation.
• PSUs are performance-based, incentivizing the achievement of specific company goals by December 31, 2028.

Negatives

• 2,123 shares of common stock were disposed of to cover tax obligations, reducing the direct beneficial ownership of the CFO by that amount.

Risks

• No specific company-level risks are detailed in this Form 4 filing, as it primarily reports insider transactions related to executive compensation.

Future Outlook

The newly granted Restricted Stock Units will vest in equal increments annually starting March 17, 2027, over a four-year period. Performance Stock Units are contingent on achieving specific performance conditions by December 31, 2028, with a potential payout range from 0% to 150% of the target amount, or 100% upon a change in control prior to that date. The stock options have a ten-year term, expiring on March 17, 2036.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one for KORU Medical Systems, are routine disclosures for publicly traded companies, detailing changes in beneficial ownership for insiders like the Chief Financial Officer. The grant of equity awards (RSUs, PSUs, and stock options) is a standard component of executive compensation packages across various industries, designed to align management incentives with shareholder interests and promote long-term retention.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including a mix of time-based RSUs, performance-based PSUs, and stock options, is a common practice among U.S. public companies, particularly in the medical device or healthcare technology sector.
• Companies like Medtronic (MDT), Boston Scientific (BSX), and Stryker (SYK) frequently utilize similar diversified equity incentive plans for their executives, aiming to balance retention with performance-driven rewards.
• The vesting schedule for RSUs (equal increments over several years) and the performance-based nature of PSUs with a defined measurement period are consistent with typical industry benchmarks for executive long-term incentive plans.

Stakeholder Impact

• Shareholders: The grant of performance-based equity awards to the CFO can align management's strategic decisions with shareholder value creation, potentially leading to improved long-term company performance.
• Employees: While specific to the CFO, such compensation structures can set a precedent for broader employee incentive programs, influencing morale and retention.

Next Steps

• The newly granted Restricted Stock Units will begin vesting on March 17, 2027, and continue annually thereafter.
• The performance conditions for the Performance Stock Units will be evaluated as of December 31, 2028.
• The stock options can be exercised at any time after their vesting date until their expiration on March 17, 2036.

Key Dates

Keywords

KORU Medical Systems, KRMD, Thomas Edward Adams, CFO, Form 4, insider trading, restricted stock units, RSUs, performance stock units, PSUs, stock options, equity compensation, executive compensation, beneficial ownership